Tiga TX
Boston
About Tiga TX
Tiga TX develops an IgA therapeutic monoclonal antibody platform to activate neutrophils for the treatment of solid tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $35.5M
- Funding stage: M&A
- Last round: Grant (Dec 2024)
- Website: tigatx.com
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/tiga-tx-74042 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.